Disc Medicine's rare disease drug hits Phase 3 goal, reviving FDA approval hopes
Disc's bitopertin succeeded in a Phase 3 trial for erythropoietic protoporphyria months after an FDA rejection, and the company now plans to re-engage regulator
Biopharmadive · +6 outlets
Roche signs $15B ADC pact with China's Hansoh, paying $400M upfront
The broad deal covers multiple antibody-drug conjugates and marks Roche's return to a Chinese ADC partner amid tightening scrutiny of cross-border biotech deals
Biopharmadive · +4 outlets
Merck KGaA to acquire Silence Therapeutics for $1.3B in RNAi bet
The deal hands the German company a Phase 2 blood disorder medicine that could compete with a Takeda drug.
Biopharmadive · +8 outlets
Trump orders creation of NIH division and task force on women's health
Melania Trump said the new research and policy initiative will set a new standard for women's health.
STAT · +14 outlets
Nouscom raises EUR 120M Series D for cancer immunotherapy programs
The oversubscribed round funds off-the-shelf cancer vaccines and clinical data in Lynch syndrome carriers being presented at ESMO.
Global Venturing · +8 outlets
FDA clears GSK drug for certain rectal cancers
The approval could shift how a subset of rectal cancers is treated and adds to GSK's oncology portfolio.
Benzinga · +14 outlets
Gilead oral IBD drug eliminates symptoms in mid-stage study
The Phase 2 result supports Gilead's push into inflammatory bowel disease, a field with several active competitors.
STAT · +3 outlets
Merck and Moderna present Phase 3 melanoma findings for personalized cancer vaccine
The combination data headlines ESMO 2026, where Merck/Moderna, Summit/Akeso and ADC developers are detailing wins and setbacks.
Intellectia AI · +14 outlets
China proposes restrictions on foreign acquisitions of critical biopharma technologies
The move aims to keep control of China's drug development industry, potentially complicating cross-border biotech M&A.
STAT · +9 outlets
AbbVie next-gen Crohn's disease combo beats Skyrizi in Phase 2
The result positions the combination as a potential successor to AbbVie's own Skyrizi in inflammatory bowel disease.
Fierce Biotech · +2 outlets
Estuary launches with $103M to advance Yale-based gene therapies
The new company is built on Yale research, adding to a wave of well-funded gene therapy startups.
AllSci · +6 outlets
New CRISPR approach targets gene fusions found in 1 in 5 cancers
The method aims at a class of cancer-driving gene fusions that are common across tumor types.
Medical Xpress · +7 outlets
FDA advisers narrowly vote to add 6 peptides to drug compounding list
The close vote could broaden compounding pharmacy access to peptides, a category with contested regulatory status.
PBS · +4 outlets
Evaxion reports positive Phase 2 trial of personalized cancer vaccine EVX-01
The data adds to a growing field of personalized cancer vaccine candidates advancing through mid-stage testing.
The Pharma Letter · +10 outlets
FDA accepts new drug application for UGN-103 in recurrent bladder cancer
The acceptance moves the intravesical therapy into the review process for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer.
Urology Times · +7 outlets
Biotech startup Aureka raises $100M Series B
The Orange County biotech's raise is one of the larger private financings reported this week.
Orange County Business Journal · +8 outlets
Isomorphic Labs faces questions on whether its AI can deliver new medicines
The Alphabet spinout is under pressure to show its drug design technology produces clinical results.
STAT · +1 outlets
FDA approves Tudriqev for advanced refractory melanoma
The approval adds a new option for melanoma patients who have progressed on prior therapy.
scanx.trade · +1 outlets